Blog

Erika Hamilton’s insights into the future of ADCs in oncology – Sarah Cannon Research Institute

Photo taken from Erika Hamilton/X

Jun 24, 2024, 13:33

Erika Hamilton’s insights into the future of ADCs in oncology – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared the following post on LinkedIn:

“We are thrilled to share the latest advancements in cancer research from our experts at Sarah Cannon Research Institute, presented at the 2024 Annual ASCO Meeting. Erika Hamilton, MD’s insights into the future of antibody-drug conjugates (ADCs) highlight exciting new possibilities in oncology. Discover more about these therapies here.”

Source: Sarah Cannon Research Institute/LinkedIn
.

2024 Annual ASCO Meeting ADCs Antibody drug conjugates ASCO 2024 ASCO Annual Meeting cancer cancer innovations Cancer research cancer therapies cancer treatment Erika Hamilton future of oncology OncoDaily Oncology oncology advancements oncology research Research Sarah Cannon Research Institute

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage